Antitumor Drug “Chlonizol”
Development and Preclinical Trials of the New Alkylnitrosourea Antitumor Drug Formulation
Tech Area / Field
- MED-DRG/Drug Discovery/Medicine
- CHE-SYN/Basic and Synthetic Chemistry/Chemistry
3 Approved without Funding
Research Center of Toxicology and Hygienic Regulation of Biopreparations, Russia, Moscow reg., Serpukhov
- Institute of Biochemical Physics, Russia, Moscow\nCancer Research Center, Russia, Moscow
Project summaryDevelopment of new effective antitumor drugs is an urgent medico-biological task. In modern chemotherapy of tumors, formulations of nitroso-alkyl-urea class (NAU, Fig.1) are top in the list of the drugs used for treatment of patients with lymphogranulomatosis, lung cancer, melanoma, or cerebrum tumors.
The proposed project is devoted to the development of original formulation related to this group of compounds with suggested name "Chlonizol" (RF patent for invention #2068843, priority August 6, 1992). Preliminary laboratory-scale testing have demonstrated that Chlonizol along with the typical for NAU preparations pharmacological properties offers in particular the ability to deeply penetrate through hemato-encephalic barrier. In addition, this substance exhibits extremely high activity against a broad spectrum of model tumors including intracerebral ones. Preliminary experimental results of Chlonizol pilot batches have proved the undoubtedly good prospects of this formulation for the further refined pre-clinical study with the purpose to obtain an antitumor drug capable of enhancing the tumor treatment efficiency, especially, with regard to neurogenic tumors.
The tasks of the project are as follows:
- Develop Chlonizol substance for conducting pre-clinical trials.
- Develop drug dosage forms- for injection and in tablets.
- Conduct integrated pre-clinical toxicological studies of the formulation.
- Conduct refined study of Chlonizol antitumor properties and mechanism of action.
- Conduct comparative study of pharmacokinetic properties of drug dosage forms in healthy animals and animals with tumors.
The data obtained during the project accomplishment will perform scientific and economical basis for Chlonizol posterior complete pre-clinical and clinical trials and for its further industrial production.
The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.
ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.